{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-046302","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2023-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.518827+00:00","generated_at":"2026-06-10T06:17:55.666190+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA accepts BLA and grants Priority Review for Rocket's RP-L201 gene therapy for severe LAD-I; PDUFA March 31, 2024","bullets":["PDUFA target action date set for March 31, 2024.","RP-L201 has FDA RMAT, Rare Pediatric, Fast Track, and Orphan Drug designations.","Rocket eligible for Priority Review Voucher if RP-L201 is approved.","Phase 1/2 data: 100% overall survival at ≥12 months for all nine patients; symptoms resolved.","RP-L201 is a lentiviral vector-based gene therapy for severe LAD-I, a fatal childhood immune disorder."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-046302","json":"https://secwatch.observer/filing/0001140361-23-046302.json","markdown":"https://secwatch.observer/filing/0001140361-23-046302.md","text":"https://secwatch.observer/filing/0001140361-23-046302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123046302/0001140361-23-046302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036123046302/ef20011759_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T06:17:55.666190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}